Dermatology Articles

• A Phase 3 Trial of Brepocitinib in Dermatomyositis May 14, 2026
  Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality.1 Treatment of myositis is based on off-label use of...
  Ingrid E. Lundberg
• A Phase 3 Trial of Brepocitinib in Dermatomyositis May 14, 2026
  In a trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose.
  Ruth Ann Vleugels, Julie J. Paik, Iazsmin Bauer Ventura, Aaron R. Mangold, Prateek C. Gandiga, Anna Haemel, Hector Chinoy, Yessar M. Hussain, Kumaraswamy Sivakumar, Zoltan Griger, Eun Bong Lee, Francisca Bozan, Chung-Yuan Hsu, Alisa Femia, Mazen M. Dimachkie, Michelle S. Min, Tahseen Mozaffar, Christina Charles-Schoeman, David R. Fernandez, Oluwakemi Onajin, Raquel Campanilho-Marques, Galina Marder, Floranne Ernste, Elena Schiopu, Jason Sluzevich, David Pearson, Stephen Lindsey, Michael Luggen, Michael R. Bubb, Erin Boh, Rashmi Maganti, Latisha Heinlen, Katharina S. Shaw, Matthew D. Cascino, Paul N. Mudd Jr., Jiri Vencovsky, Anthony P. Fernandez, David Fiorentino, Lisa Christopher-Stine, Victoria P. Werth, Rohit Aggarwal, the VALOR Investigators*
• Erythema Multiforme May 7, 2026
  A 22-year-old man presented with a 5-day history of painful lesions on his hands, feet, lips, and tongue. Physical examination showed erosions on the tongue and target lesions on the palms.
  Inês Pereira Amaral, Joana Antunes